metoprolol has been researched along with Proteinuria in 12 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 9.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "Antihypertensive treatment with enalapril reduced proteinuria in patients with diabetic nephropathy more than an equally effective antihypertensive treatment with metoprolol." | 9.06 | Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. ( Aurell, M; Björck, S; Johnsen, SA; Mulec, H; Nyberg, G, 1990) |
| "Glycosuria, hyperglycemia, and nephrotic-range proteinuria developed in a 68-year-old patient after clonidine was added to a stable antihypertensive regimen, which included metoprolol, of three years' duration." | 7.67 | Nephrotic-range proteinuria and hyperglycemia associated with clonidine therapy. ( Josselson, J; Sadler, JH, 1986) |
| "The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] < or =92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol)." | 5.11 | Blood pressure control, drug therapy, and kidney disease. ( Agodoa, LY; Cheek, D; Contreras, G; Dowie, D; Greene, T; Junco, G; Lash, J; Lipkowitz, M; Miller, ER; Ojo, A; Sika, M; Toto, RD; Wilkening, B, 2005) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 5.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "In a double-blind, randomized trial with 26 male white patients with essential hypertension in World Health Organization Stages I and II, we examined the impact of calcium entry blockade (5 to 10 mg/day isradipine, N = 14) and beta-blockade (100 to 200 mg/day metoprolol, N = 12) on early markers of hypertensive nephropathy before and after 7 weeks' treatment." | 5.07 | Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy. ( Rockstroh, J; Rüddel, H; Schächinger, H; Schlebusch, H; Schmieder, RE; Schulte, W, 1992) |
| "Antihypertensive treatment with enalapril reduced proteinuria in patients with diabetic nephropathy more than an equally effective antihypertensive treatment with metoprolol." | 5.06 | Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. ( Aurell, M; Björck, S; Johnsen, SA; Mulec, H; Nyberg, G, 1990) |
| "Glycosuria, hyperglycemia, and nephrotic-range proteinuria developed in a 68-year-old patient after clonidine was added to a stable antihypertensive regimen, which included metoprolol, of three years' duration." | 3.67 | Nephrotic-range proteinuria and hyperglycemia associated with clonidine therapy. ( Josselson, J; Sadler, JH, 1986) |
| "The magnitude of proteinuria is associated with a graded increase in the risk of progression to end-stage renal disease and cardiovascular events." | 2.71 | The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. ( Bakris, GL; Greene, T; Hebert, L; Lea, J; Lipkowitz, M; Massry, S; Middleton, J; Miller, E; Rostand, SG; Smith, W, 2005) |
| "Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD." | 2.70 | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002) |
| "Both treatments reduced proteinuria not only in hypertensive, but also in normotensive patients." | 2.67 | Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis. ( Huysmans, FT; Kloke, HJ; Koene, RA; van Hamersvelt, HW; Wetzels, JF, 1993) |
| "Treatment with enalapril can reduce the rate of decline in kidney function in patients with diabetic nephropathy more than equally effective antihypertensive treatment with metoprolol." | 2.67 | Renal protective effect of enalapril in diabetic nephropathy. ( Aurell, M; Björck, S; Johnsen, SA; Mulec, H; Nordén, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wright, JT | 2 |
| Bakris, G | 1 |
| Greene, T | 4 |
| Agodoa, LY | 3 |
| Appel, LJ | 1 |
| Charleston, J | 2 |
| Cheek, D | 3 |
| Douglas-Baltimore, JG | 1 |
| Gassman, J | 2 |
| Glassock, R | 1 |
| Hebert, L | 3 |
| Jamerson, K | 2 |
| Lewis, J | 1 |
| Phillips, RA | 2 |
| Toto, RD | 3 |
| Middleton, JP | 1 |
| Rostand, SG | 2 |
| Lea, J | 2 |
| Lipkowitz, M | 3 |
| Massry, S | 2 |
| Middleton, J | 2 |
| Miller, E | 1 |
| Smith, W | 2 |
| Bakris, GL | 2 |
| Contreras, G | 1 |
| Junco, G | 1 |
| Dowie, D | 2 |
| Lash, J | 2 |
| Miller, ER | 2 |
| Ojo, A | 2 |
| Sika, M | 1 |
| Wilkening, B | 1 |
| Mulec, H | 3 |
| Johnsen, SA | 3 |
| Björck, S | 3 |
| Kloke, HJ | 1 |
| Wetzels, JF | 1 |
| van Hamersvelt, HW | 1 |
| Koene, RA | 1 |
| Huysmans, FT | 1 |
| Shiigai, T | 1 |
| Hattori, K | 1 |
| Iwamoto, H | 1 |
| Owada, A | 1 |
| Appel, L | 1 |
| Beck, G | 1 |
| Bourgoignie, J | 1 |
| Briggs, JP | 1 |
| Cleveland, W | 1 |
| Douglas, JG | 1 |
| Douglas, M | 1 |
| Faulkner, M | 1 |
| Gabriel, A | 1 |
| Hall, Y | 1 |
| Hiremath, L | 1 |
| Johnson, CJ | 1 |
| Kopple, J | 1 |
| Kusek, J | 1 |
| Lewis, JB | 1 |
| Norris, K | 1 |
| O'Connor, D | 1 |
| Pogue, V | 1 |
| Rahman, M | 1 |
| Randall, OS | 1 |
| Rostand, S | 1 |
| Schulman, G | 1 |
| Thornley-Brown, D | 1 |
| Tisher, CC | 1 |
| Xu, S | 1 |
| Schmieder, RE | 1 |
| Rüddel, H | 1 |
| Schlebusch, H | 1 |
| Rockstroh, J | 1 |
| Schächinger, H | 1 |
| Schulte, W | 1 |
| Nordén, G | 1 |
| Aurell, M | 2 |
| Nordlander, M | 1 |
| Havu, N | 1 |
| Nyberg, G | 1 |
| Josselson, J | 1 |
| Sadler, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023] | Phase 4 | 106 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Multicentre Prospective Open Label Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.[NCT04662723] | Phase 4 | 878 participants (Anticipated) | Interventional | 2023-05-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 trials available for metoprolol and Proteinuria
| Article | Year |
|---|---|
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blac | 2005 |
Blood pressure control, drug therapy, and kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Long-term enalapril treatment in diabetic nephropathy.
Topics: Adult; Blood Pressure; Diabetic Nephropathies; Enalapril; Glomerular Filtration Rate; Humans; Metopr | 1994 |
Angiotensin-converting enzyme inhibition and the combination of a beta blocker and a diuretic are equally effective in lowering proteinuria in patients with glomerulonephritis.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Chlorthalidone; Drug Combinations; Fe | 1993 |
Long-term enalapril therapy in patients with chronic renal failure on a low-protein diet. A prospective randomized comparison with metoprolol.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cholesterol, HDL; Creatinine; Diet, Protein-Re | 1998 |
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2001 |
Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hypertensive nephropathy.
Topics: Antihypertensive Agents; Dihydropyridines; Double-Blind Method; Humans; Hypertension; Isradipine; Ki | 1992 |
Renal protective effect of enalapril in diabetic nephropathy.
Topics: Adult; Blood Pressure; Diabetic Nephropathies; Enalapril; Glomerular Filtration Rate; Humans; Kidney | 1992 |
Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy.
Topics: Adult; Albuminuria; Blood Pressure; Diabetic Nephropathies; Enalapril; Humans; Metoprolol; Middle Ag | 1990 |
2 other studies available for metoprolol and Proteinuria
| Article | Year |
|---|---|
Effects of chronic felodipine treatment on renal function and morphology in SHR.
Topics: Animals; Blood Pressure; Creatinine; Drug Synergism; Felodipine; Female; Glomerulosclerosis, Focal S | 1992 |
Nephrotic-range proteinuria and hyperglycemia associated with clonidine therapy.
Topics: Aged; Clonidine; Drug Synergism; Glycosuria; Humans; Hyperglycemia; Insulin; Male; Metoprolol; Prote | 1986 |